(2) Supplemental Information Disclosure Statement, a PTO Form 1449 and the references cited therein.

Amendment

In the Claims:

Please cancel claims 19-46, without prejudice and disclaimer and add the following new claims:

--47. (New) A method for producing an authentic, properly folded insulin-like growth factor (IGF) polypeptide from a yeast cell medium comprising the IGF polypeptide, wherein the method comprises:

(a) performing a first cation exchange chromatography with the yeast cell medium to obtain a partially purified IGF mixture;

(b) denaturing and renaturing partially purified IGF species;

(c) subjecting renatured IGF species to hydrophobic interaction chromatography; and

(d) performing reverse phase high performance liquid chromatography to obtain a further purified IGF mixture, wherein the further purified IGF mixture has a greater amount of authentic, properly folded IGF than the partially purified IGF mixture.

48. The method of claim 47, wherein the method further comprises performing a second cation exchange chromatography prior to performing reverse phase high performance liquid chromatography.

49. The method of claim 47, wherein the method further comprises raising the pH of the yeast cell medium which comprises yeast cells to about pH 8 to about pH 12, prior to the first cation exchange chromatography.

50. The method of claim 49, wherein the method comprises raising the pH of the yeast cell medium which comprises yeast cells to about pH 10 to about pH 11, prior to the first cation exchange chromatography.

51. The method of claim 47, wherein the first cation exchange chromatography is performed using a sulfopropylated matrix.

52. The method of claim 48, wherein the second cation exchange chromatography is performed using a sulfopropylated matrix.

53. The method of claim 47, wherein the denaturing and renaturing steps are performed together using a denaturation buffer comprising urea, dithiothreitol, alcohol and salt, in sufficient amounts and under conditions which allow for the reduction and subsequent oxidation of disulfide bonds.

54. The method of claim 53, wherein the denaturation buffer comprises about 1 to about 4 M urea, about 1 mM to about 75 mM sodium borate, about .5 M to about 3 M sodium chloride, about 10% to about 30% ethanol and about 0.5- to about 7-fold molar excess of dithiothreitol.

55. The method of claim 54, wherein the denaturation buffer comprises about 1.5 M to about 3 M urea, about 3 to about 50 mM sodium borate, about 1 M to about 1.5 M sodium chloride, about 15% to about 25% ethanol, and about an equimolar to about a 5-fold molar excess of dithiothreitol.

56. The method of claim 47, wherein the hydrophobic interaction chromatography is performed using a polyethyleneamine matrix.

57. The method of claim 8, wherein the hydrophobic interaction chromatography is performed using a butyl- or phenyl-substituted poly(methacrylate) matrix.

58. The method of claim 47, wherein the reverse phase high performance liquid chromatography is performed using a C_3 silica-derivatized resin.

59. The method of claim 47, wherein the yeast cell is *Pichia sp.*

B1 amended

60. The method of claim 59, wherein the yeast cell is *P. pastoris.*

61. The method of claim 47, wherein the yeast cell is *Saccharomyces sp.*

62. The method of claim 61, wherein the yeast cell is *S. cerevisiae.*

63. The method of claim 47, wherein the IGF is IGF-I or an analog thereof.

64. The method of claim 63, wherein the IGF is IGF-I.--